Cardurion Pharmaceuticals

📍 Boston, United States🗓 Founded 2017👥 9 employees
Biotechnology🌐 cardurion.com
Website LinkedIn
Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion’s product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Cardurion Pharmaceuticals founded?
Cardurion Pharmaceuticals was founded in 2017.
What industry is Cardurion Pharmaceuticals in?
Cardurion Pharmaceuticals operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Cardurion Pharmaceuticals based?
Cardurion Pharmaceuticals is headquartered in Boston, United States.